Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes

Haematologica. 2015 Apr;100(4):499-510. doi: 10.3324/haematol.2014.112276. Epub 2015 Jan 23.

Abstract

Overwhelming evidence identifies the microenvironment as a critical factor in the development and progression of chronic lymphocytic leukemia, underlining the importance of developing suitable translational models to study the pathogenesis of the disease. We previously established that stable expression of kinase dead protein kinase C alpha in hematopoietic progenitor cells resulted in the development of a chronic lymphocytic leukemia-like disease in mice. Here we demonstrate that this chronic lymphocytic leukemia model resembles the more aggressive subset of chronic lymphocytic leukemia, expressing predominantly unmutated immunoglobulin heavy chain genes, with upregulated tyrosine kinase ZAP-70 expression and elevated ERK-MAPK-mTor signaling, resulting in enhanced proliferation and increased tumor load in lymphoid organs. Reduced function of PKCα leads to an up-regulation of PKCβII expression, which is also associated with a poor prognostic subset of human chronic lymphocytic leukemia samples. Treatment of chronic lymphocytic leukemia-like cells with the selective PKCβ inhibitor enzastaurin caused cell cycle arrest and apoptosis both in vitro and in vivo, and a reduction in the leukemic burden in vivo. These results demonstrate the importance of PKCβII in chronic lymphocytic leukemia-like disease progression and suggest a role for PKCα subversion in creating permissive conditions for leukemogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Lymphocytes / metabolism*
  • B-Lymphocytes / pathology
  • Cell Proliferation / drug effects
  • Disease Models, Animal
  • Disease Progression
  • Gene Expression Regulation, Leukemic*
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunoglobulin Variable Region / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • Leukemic Infiltration / pathology
  • Lymphoid Tissue / pathology
  • Mice
  • Mice, Knockout
  • Prognosis
  • Protein Kinase C beta / antagonists & inhibitors
  • Protein Kinase C beta / genetics*
  • Protein Kinase C beta / metabolism
  • Protein Kinase C-alpha / genetics*
  • Protein Kinase C-alpha / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Transduction, Genetic
  • Tumor Burden / drug effects
  • ZAP-70 Protein-Tyrosine Kinase / genetics
  • ZAP-70 Protein-Tyrosine Kinase / metabolism

Substances

  • Immunoglobulin Heavy Chains
  • Immunoglobulin Variable Region
  • Protein Kinase Inhibitors
  • ZAP-70 Protein-Tyrosine Kinase
  • Protein Kinase C beta
  • Protein Kinase C-alpha